Temple Garden Chambers is a leading common law set based in London and The Hague.
With excellence from top to bottom Chambers provides a first class service in a number of different fields.
Dr Mary-Teresa Deignan represented an orthopaedic surgeon charged with dishonestly failing to disclose, in response to an express question on an application form, that he was being investigated by the GMC for sexually motivated conduct towards a patient, an investigation…
Dr Mary-Teresa Deignan Successfully resisted an appeal on the instruction of the CQC against a decision of the CQC to cancel the registration of a provider of healthcare services. The hearing involved five witnesses and took place remotely via Kinley…
Dr Mary-Teresa Deignan represented Helen Lockett, former Director of Operations and Executive Nurse at Liverpool Community NHS Trust, over 94 days. Allegations of misconduct, including concealing concerns, bullying and the downgrading of risks, arose in the context of upheaval in…
Dr Mary-Teresa Deignan represented Emma Short, the Service Manager for an Inpatient Unit for people with learning disabilities where, in 2013, Connor Sparrowhawk had an epileptic fit in the bath a died. After an inquest in 2015 found that his…
The high profile police investigation ‘Operation Jasmine’ founded allegations of serious neglect in a number of nursing care homes in Wales. Dr Mary-Teresa Deignan instructed by the NMC to present these three linked cases.
Dr Mary-Teresa Deignan was instructed by the NMC in these widely-reported proceedings. Whilst working at the Institute of Ageing and Health in the West Midlands the registrant was asked by members of her family to provide bereavement counselling to a…
Represented, with John Greenbourne, the claimant. The Supreme Court reversed the Court of Appeal’s decision upholding the claim for professional negligence, and identified a clear line between what a claimant must prove before the assessment of the lost chance takes…
Nicholas Chapman advised the Financial Reporting Council concerning its investigation into the circumstances surrounding the flotation and subsequent collapse of a former AIM new company of the year, with a market capitalisation effect of around £150m.
Case involving conduct of a UK based multi-centre industry sponsored medical device clinical trial.
